TactiFlex Ablation Catheter, Sensor Enabled, TactiSys Quartz Equipment, TactiSys Quartz, TactiFlex Radiofrequency C
ABBOTT MEDICAL · Decision date May 18, 2023
What did the FDA approve?
FDA records P220013 as an original PMA application. The recorded decision is approval, dated May 18, 2023.
FDA approval order statement
Approval for the TactiFle Ablation Catheter, Sensor Enabled. This device is indicated for use in cardiac electrophysiological mapping and for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used in conjunction with a compatible RF generator and three-dimensional mapping system.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- May 18, 2023
Regulatory record facts
- Identifier
- P220013
- Regulatory pathway
- Premarket approval application
- Applicant
- ABBOTT MEDICAL
- Product code
- OAE
- Decision code
- APPR
- Decision date
- May 18, 2023
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.
- Applicant
- Abbott Medical
- Product code
- OAE
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P220013 received
Application receipt date recorded by FDA.
P220013 · FDA decision
APPR
P220013/S028 · Related supplement
TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDM
P220013/S034 · Related supplement
TactiFlex Ablation Catheter, Sensor Enabled
Timeline entries are records held by MedtechLedger for P220013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Sep 4, 2026 | FDA | |
TactiFlex Ablation Catheter, Sensor EnabledP220013/S034 | ABBOTT MEDICAL | PMA supplement | Sep 22, 2026 | FDA |
Explore the linked device profile
Other records with product code OAE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
STOP Persistent AFP100010/S154 | Medtronic Cryocath, LP | PMA supplement | Sep 25, 2026 | FDA |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
QDOT MICRO SystemP210027/S018 | Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA |
QDOT MICRO SystemP210027 | Biosense Webster, Inc. | PMA approval | Nov 23, 2022 | FDA |
| Medtronic Cryocath, LP | PMA approval | Dec 17, 2010 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 5050 Nathan Ln. N., Plymouth, MN, 55442
Sources and methodology
- Original FDA record: P220013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


